Using pharmacoeconomic modelling to determine value-based pricing for new pharmaceuticals in malaysia

Malaysian Journal of Medical Sciences

Volumn 18, Issue 4, 2011, Pages 31-42

  Dranitsaris, George ^a   Truter, Ilse ^a   Lubbe, Martie S ^b   N, Nitin ^c   Mendonca, Vivian M ^c   Mahagaonkar, Sangameshwar B ^c  

^a NELSON MANDELA METROPOLITAN UNIVERSITY   (South Africa)

^b NORTH WEST UNIVERSITY   (South Africa)

^c PharmARC Analytic Solutions   (India)

Author keywords

Chemotherapy; Cost analysis; Drug costs; Folfox protocol; Pharmacoeconomics

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG COST; HEALTH CARE SYSTEM; HUMAN; MALAYSIA; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; SURVIVAL RATE;

EID: 80053592434     PISSN: 1394195X     EISSN: 21804303     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Orszag PR, Ellis P. The challenge of rising health care costs-A view from the Congressional Budget Offce. N Engl J Med. 2007;357(18):1793-1795.
2. Hoffman JM, Shah ND, Vermeulen LC, Doloresco F, Martin PK, Blake S, et al. Projecting future drug expenditures-2009. Am J Health Syst Pharm. 2009;66(3):237-257.
3. Arenas-Guzman R, Tosti A, Hay R, Haneke E. Pharmacoeconomics-An aid to better decision-making. J Eur Acad Dermatol Venereol. 2009; 19 Suppl 1:34-39.
4. Guidelines for the economic evaluation of health technologies: Canada [Internet]. 3rd ed. Ottawa (CA): Canadian Agency for Drugs and Technologies in Health; 2006 [cited 2009 Nov 18]. Available from: http://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf.
5. Weinstein MC, Fineberg HV. Clinical decision analysis. Philadephia (PA): WB Saunders; 1980.
6. Drummond MF, Mason AR. European perspective on the costs and cost-effectiveness of cancer therapies. J Clin Oncol. 2007;25(2):191-195.
7. Wilking N, Jonsson B. A Pan European comparison regarding patient access to cancer drugs. Stockholm (SE): Karolinska Institutet, Stockholm School of Economics; 2005.
8. Hillner BE, Smith TJ. Effcacy does not necessarily translate to cost effectiveness: A case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol. 2009;27(13):2111-2113.
9. Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines in generalized cost-effectiveness analysis. Health Econ. 2000;9(3): 235-251.
10. The world factbook [Internet]. Washington (DC): Central Intelligence Agency; 2009 [cited 2010 Sep 18]. Available from: https://www.cia.gov/library/publications/the-world-factbook/rankorder/20 04rank.html.
11. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as frst-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol. 2008;26(12):2013-2019.
12. Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan. Clin Ther. 2007;29(10):2256-2267.
13. Tappenden P, Jones R, Paisley S, Carroll C. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess. 2007;11(12):1-128, iii-iv.
14. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fuorouracil compared with fuorouracil alone as frst-line treatment for metastatic colorectal cancer: A multicentre randomized trial. Lancet. 2000;355(9209):1041-1047.
15. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fuorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23-30.
16. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol. 2004;22(2):229-237.
17. Engstrom PF. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy. Pharmacotherapy. 2008; 28(11 Pt 2):18S-22S.18.
18. Sonnenberg FA, Beck RJ. Markov models in medical decision making: A practical guide. Med Decis Making. 1993;13(4):322-332.
19. Torrance GW. Utility approach to measuring health-related quality of life. J Chron Dis. 1987;40(6): 593-603.
20. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(14):1172-1177.
21. Leung P, Tanock IF, Oza AM, Puodziunas A, Dranitsaris G. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol. 1999;17(10):3082-3090.
22. Ortega A, Dranitsaris G, Sturgeon J, Sutherland H, Oza A. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol. 1997;66(3):454-463.